Skip to main content
Premium Trial:

Request an Annual Quote

BGI Genomics Gets Australian Regulatory Approval for Multiplexed SARS-CoV-2, Influenza Test

NEW YORK – BGI Genomics said on Friday that its multiplexed test for SARS-CoV-2, influenza A, and influenza B is now included in the Australian Register of Therapeutic Goods.

The Chinese genomics company, based in Shenzhen, said the real-time fluorescent RT-PCR test was developed for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples in a single reaction.

​​The designation clears the assay’s entrance to the Australian market, accelerating the company’s rapid growth in the international market, BGI Genomics said in a statement.

BGI Genomics previously received CE marking for two multiplexed tests for SARS-CoV-2 and influenza A/B manufactured by its subsidiary BGI PathoGenesis Pharmaceutical Technology in September 2020.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.